Literature DB >> 25902887

Opening of native aortic valve accomplished after left ventricular assist device implantation in patients with insufficient preoperative Beta-blocker treatment.

Teruhiko Imamura1, Koichiro Kinugawa, Daisuke Nitta, Toshiro Inaba, Hisataka Maki, Masaru Hatano, Osamu Kinoshita, Kan Nawata, Shunei Kyo, Minoru Ono.   

Abstract

Although we recently demonstrated that opening of a native aortic valve (AV) after left ventricular assist device (LVAD) implantation is a sufficient condition to prevent development of aortic insufficiency (AI), its preoperative predictors remain unknown. Data were obtained from 58 patients who had been treated with continuous flow LVAD for ≥ 6 months at our institute between 2006 and 2014. Opening of native AV was accomplished in 21 patients (36%) at postoperative 6 months. Uni/Multivariate logistic regression analyses demonstrated that a preoperative lower cumulative dose of β-blocker was the only independent predictor for postoperative opening of native AV (P = 0.020, OR 0.905) at the cutoff level of 4.5g (equivalent dose of carvedilol), calculated by an ROC analysis. Prevalence of native AV opening was increased gradually along with improvement of LV ejection fraction only in patients with preoperative insufficient β-blocker treatment during postoperative 6 months (P < 0.05 for both). Patients with opening of native AV had higher exercise capacity and a lower re-admission rate than those with closed native AV during 2-year LVAD support (5% versus 44%, P < 0.05). Opening of native AV during LVAD support is profoundly associated with LV reverse remodeling especially in patients with insufficient preoperative β-blocker exposure probably due to their better responsiveness to combination therapy with β-blocker and LVAD. Patients who accomplished native AV opening can enjoy better exercise performance and avoid re-admission due to cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25902887     DOI: 10.1536/ihj.14-330

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  1 in total

1.  Benefits of Neurohormonal Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices.

Authors:  Rayan Yousefzai; Michela Brambatti; Hao A Tran; Rachel Pedersen; Oscar Ö Braun; Tina Baykaner; Roxana Ghashghaei; Nasir Z Sulemanjee; Omar M Cheema; Matthew Rappelt; Carmela Baeza; Abdulaziz Alkhayyat; Yang Shi; Victor Pretorius; Barry Greenberg; Eric Adler; Vinay Thohan
Journal:  ASAIO J       Date:  2020-04       Impact factor: 2.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.